This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier:
NCT00929851
First received: June 29, 2009
Last updated: March 28, 2017
Last verified: March 2017
June 29, 2009
March 28, 2017
October 2009
March 2012   (Final data collection date for primary outcome measure)
Exacerbation rate Change in pre-dose FEV1 [ Time Frame: 0-4-12-24-36-48 weeks ]
Same as current
Complete list of historical versions of study NCT00929851 on ClinicalTrials.gov Archive Site
Pulmonary function parameters(FEV1 - FVC) St George's Questionnaire Use of rescue medication [ Time Frame: 0-4-12-24-36-48 weeks ]
Same as current
Not Provided
Not Provided
 
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
a 48-week, Double Blind, Randomized, Multinational, Multicentre, "Fixed Combination" Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease
a 48-week, 2-arm parallel group, "fixed combination" beclomethasone dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary disease
a 48-week, double blind, randomized, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" beclomethasone dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary disease
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pulmonary Disease, Chronic Obstructive
  • Drug: CHF1535
    Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
    Other Name: Foster, Fostair
  • Drug: Formoterol fumarate
    Formoterol fumarate 12 µg per metered dose
    Other Name: Atimos
  • Experimental: BDP/FF
    Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
    Intervention: Drug: CHF1535
  • Active Comparator: Formoterol fumarate
    Formoterol fumarate 12 µg per metered dose
    Intervention: Drug: Formoterol fumarate

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1199
July 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Severe COPD
  • At least one COPd exacerbation in previous year

Exclusion Criteria:

  • Asthma, allergic rhinitis or other atopic disease
  • Unstable concurrent disease:
  • Evidence of heart failure
Sexes Eligible for Study: All
40 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00929851
CCD-0906-PR-0016
2009-012546-23 ( EudraCT Number )
Yes
Not Provided
Not Provided
Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici S.p.A.
Not Provided
Principal Investigator: Jadwiga A Wedzicha, MD, Prof UCL MEDICAL SCHOOL
Chiesi Farmaceutici S.p.A.
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP